Nathan Hotaling

Nathan Hotaling

Auto-generated profile, based on publicly available information

Nathan Hotaling

National Center for Advancing Translational Science, National Institutes of Health, Rockville, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Biomaterials
Verified
Journal Article
Closed access
NHNathan A. Hotaling
Nathan A. Hotaling
KBKapil Bharti
Kapil Bharti
HKHaydn Kriel
Haydn Kriel
CSCarl Simon
Carl Simon

10 July 2023 in Histochemistry and Cell Biology
Verified
Journal Article
Open access
PDF file
JMJosh Moore
Josh Moore
DBDaniela Basurto-Lozada
Daniela Basurto-Lozada
SBSébastien Besson
Sébastien Besson
JBJohn Bogovic
John Bogovic
JBJordão Bragantini
Jordão Bragantini
JSJason R. Swedlow
Jason R. Swedlow
A growing community is constructing a next-generation file format (NGFF) for bioimaging to overcome problems of scalability and heterogeneity. Organized by the Open Microscopy Environment (OME), individuals and institutes across diverse modalities facing these problems have designed a format specification process (OME-NGFF) to address these needs. This paper brings together a wide range of those community members to describe the cloud-optimized format itself—OME-Zarr—along with tools and data resources available today to increase FAIR access and remove barriers in the scientific process. The current momentum offers an opportunity to unify a key component of the bioimaging domain—the file format that underlies so many personal, institutional, and global data management and analysis tasks.

7 December 2015 in Annual Review of Biomedical Engineering
Verified
Journal Article
Open access
NHNathan A. Hotaling
Nathan A. Hotaling
LTLi Tang
Li Tang
DIDarrell J. Irvine
Darrell J. Irvine
JBJulia E. Babensee
Julia E. Babensee
Strategies to enhance, suppress, or qualitatively shape the immune response are of importance for diverse biomedical applications, such as the development of new vaccines, treatments for autoimmune diseases and allergies, strategies for regenerative medicine, and immunotherapies for cancer. However, the intricate cellular and molecular signals regulating the immune system are major hurdles to predictably manipulating the immune response and developing safe and effective therapies. To meet this challenge, biomaterials are being developed that control how, where, and when immune cells are stimulated in vivo, and that can finely control their differentiation in vitro. We review recent advances in the field of biomaterials for immunomodulation, focusing particularly on designing biomaterials to provide controlled immunostimulation, targeting drugs and vaccines to lymphoid organs, and serving as scaffolds to organize immune cells and emulate lymphoid tissues. These ongoing efforts highlight the many ways in which biomaterials can be brought to bear to engineer the immune system.

1 October 2012 in Journal of Engineering Education
Verified
Journal Article
Closed access
PDF file
NHNathan Hotaling
Nathan Hotaling
BFBarbara Burks Fasse
Barbara Burks Fasse
LBLewis F. Bost
Lewis F. Bost
CHChristopher D. Hermann
Christopher D. Hermann
CFCraig R. Forest
Craig R. Forest

3 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMelissa Li
Melissa Li
NHNathan A. Hotaling
Nathan A. Hotaling
DKDavid N. Ku
David N. Ku
CFCraig R. Forest
Craig R. Forest
The mainstay of treatment for thrombosis, the formation of occlusive platelet aggregates that often lead to heart attack and stroke, is antiplatelet therapy. Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect and ineffective dosing. Shear rate is also suspected to play a major role in thrombosis, but instrumentation to measure its influence has been limited by flow conditions, agonist use, and non-systematic and/or non-quantitative studies. In this work we measured occlusion times and thrombus detachment for a range of initial shear rates (500, 1500, 4000, and 10000 s−1) and therapy concentrations (0–2.4 µM for eptifibatide, 0–2 mM for acetyl-salicylic acid (ASA), 3.5–40 Units/L for heparin) using a microfluidic device. We also measured complete blood counts (CBC) and platelet activity using whole blood impedance aggregometry. Effects of shear rate and dose were analyzed using general linear models, logistic regressions, and Cox proportional hazards models. Shear rates have significant effects on thrombosis/dose-response curves for all tested therapies. ASA has little effect on high shear occlusion times, even at very high doses (up to 20 times the recommended dose). Under ASA therapy, thrombi formed at high shear rates were 4 times more prone to detachment compared to those formed under control conditions. Eptifibatide reduced occlusion when controlling for shear rate and its efficacy increased with dose concentration. In contrast, the hazard of occlusion from ASA was several orders of magnitude higher than that of eptifibatide. Our results show similar dose efficacy to our low shear measurements using whole blood aggregometry. This quantitative and statistically validated study of the effects of a wide range of shear rate and antiplatelet therapy doses on occlusive thrombosis contributes to more accurate understanding of thrombosis and to models for optimizing patient treatment.

17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NSNicholas J Schaub
Nicholas J Schaub
NHNathan A. Hotaling
Nathan A. Hotaling
PMPetre Manescu
Petre Manescu
SPSarala Padi
Sarala Padi
QWQin Wan
Qin Wan
KBKapil Bharti
Kapil Bharti
Increases in the number of cell therapies in the preclinical and clinical phases have prompted the need for reliable and non-invasive assays to validate transplant function in clinical biomanufacturing. We developed a robust characterization methodology composed of quantitative bright-field absorbance microscopy (QBAM) and deep neural networks (DNNs) to non-invasively predict tissue function and cellular donor identity. The methodology was validated using clinical-grade induced pluripotent stem cell derived retinal pigment epithelial cells (iPSC-RPE). QBAM images of iPSC-RPE were used to train DNNs that predicted iPSC-RPE monolayer transepithelial resistance, predicted polarized vascular endothelial growth factor (VEGF) secretion, and matched iPSC-RPE monolayers to the stem cell donors. DNN predictions were supplemented with traditional machine learning algorithms that identified shape and texture features of single cells that were used to predict tissue function and iPSC donor identity. These results demonstrate non-invasive cell therapy characterization can be achieved with QBAM and machine learning.